A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Macrogenics Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 661,914 shares of MGNX stock, worth $2.16 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
661,914
Previous 475,056 39.33%
Holding current value
$2.16 Million
Previous $2.02 Million 7.88%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$3.0 - $5.55 $560,574 - $1.04 Million
186,858 Added 39.33%
661,914 $2.18 Million
Q2 2024

Aug 09, 2024

BUY
$3.31 - $18.51 $187,921 - $1.05 Million
56,774 Added 13.57%
475,056 $2.02 Million
Q1 2024

May 09, 2024

BUY
$9.77 - $21.47 $1.7 Million - $3.74 Million
174,086 Added 71.29%
418,282 $6.16 Million
Q4 2023

Feb 09, 2024

BUY
$4.48 - $10.11 $470,153 - $1.06 Million
104,945 Added 75.36%
244,196 $2.35 Million
Q3 2023

Nov 13, 2023

BUY
$4.48 - $6.19 $623,844 - $861,963
139,251 New
139,251 $648,000
Q3 2022

Nov 10, 2022

BUY
$3.01 - $5.22 $66,563 - $115,435
22,114 Added 10.02%
242,909 $840,000
Q2 2022

Aug 05, 2022

BUY
$2.25 - $9.99 $394,519 - $1.75 Million
175,342 Added 385.77%
220,795 $651,000
Q1 2022

May 12, 2022

BUY
$8.12 - $16.9 $45,934 - $95,603
5,657 Added 14.21%
45,453 $400,000
Q4 2021

Feb 10, 2022

BUY
$15.91 - $21.88 $56,130 - $77,192
3,528 Added 9.73%
39,796 $639,000
Q3 2021

Nov 12, 2021

BUY
$19.74 - $28.7 $715,930 - $1.04 Million
36,268 New
36,268 $759,000
Q2 2020

Aug 13, 2020

SELL
$5.2 - $29.12 $341,218 - $1.91 Million
-65,619 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$4.28 - $12.11 $154,054 - $435,887
35,994 Added 121.5%
65,619 $381,000
Q4 2019

Feb 12, 2020

BUY
$7.95 - $12.27 $235,518 - $363,498
29,625 New
29,625 $322,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.